A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in Combination with Atezolizumab Compared with Atezolizumab as Maintenance Therapy in Participants with Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following First-Line Induction Therapy with Carboplatin, Etoposide and Atezolizumab (CTMS# 22-0017)
Lay Description
Category
- Cancers and Other Neoplasms
- Lungs, Breathing and Bronchial
- IRB Number
- 20220147HU
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- Eligible Genders
- Accepts Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Frances Crawford
(210) 450-5037
crawfordf1@uthscsa.edu
Sonia Creighton
(210) 450-1366
creighton@uthscsa.edu
Myrna Montenegro
(210) 450-5954
montenegro@uthscsa.edu
Courtney Nichols
(210) 450-1794
nicholsc2@uthscsa.edu
Mailbox Ctrc Regulatory Affairs
regaffapp@uthscsa.edu
Kathleen Rodriguez
(210) 450-1365
rodriguezk3@uthscsa.edu
Benjamin Schleif
(210) 450-1366
schleifb@uthscsa.edu
Morgan Seekatz
(210) 450-1133
seekatz@uthscsa.edu
Principal Investigator
Sherri Cervantez